Blum, Lea Alexandra
Ahrens, Birgit
Klimek, Ludger
Beyer, Kirsten
Gerstlauer, Michael
Hamelmann, Eckard
Lange, Lars
Nemat, Katja
Vogelberg, Christian
Blumchen, Katharina
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 31 August 2021
Accepted: 8 September 2021
First Online: 6 December 2021
Conflict of interest
: L. Klimek reports grants and personal fees from Allergopharma, grants and personal fees from MEDA/Mylan, personal fees from HAL Allergie, grants from ALK Abelló, grants and personal fees from LETI Pharma, grants from Stallergenes, grants from Quintiles, Grants and personal fees from Sanofi, Grants from ASIT biotech, Grants from Lofarma, Personal fees from Allergy Therapeut, Grants from AstraZeneca, Grants from GSK, Grants from Inmunotk, Personal fees from Cassella med, outside submitted work; and membership: AeDA, DGHNO, German Academy of Allergology and Clinical Immunology, ENT-BV, GPA, EAACI. B. Ahrens states that the contents and positions expressed in this paper reflect the personal expert opinion of the author and should not be interpreted or quoted as if they had been commissioned by or reflected the position of the competent national higher federal authority, the European Medicines Agency or one of its committees or working groups. Dr. K. Beyer reports grants and personal fees from Danone/Nutricia/Milupa, grants and personal fees from DBV, grants and personal fees from Hipp, grants and personal fees from Hycor, grants and personal fees from Infectopharm, personal fees from Jenapharma, personal fees from Mylan/Meda, personal fees from Nestle, personal fees from Novartis, personal fees from ThermoFisher, grants and personal fees from Aimmune, personal fees from Bencard, personal fees from ALK, outside the submitted work. M. Gerstlauer reports personal fees from Aimmune, outside the submitted work. L. Lange claims to have been a paid consultant for Aimmune, DBV Technologies and Nestlé. He has given paid lectures for Aimmune, DBV Technologies, Nestlé and Nutricia. Dr. C. Vogelberg reports personal fees from Advisory Board and Lectures for Aimmune Therapeutics, and personal fees from Advisory Board and Lectures for DBV Technology outside the submitted work. Dr K. Blumchen reports personal fees from Thermofisher Scientific; grants, personal fees, and nonfinancial support from Aimmune Therapeutics; grants, personal fees, and nonfinancial support from DBV Technologies; grants from Hipp GmbH; personal fees from Novartis,Allergy therapeutics, HAL, ALK, Allergopharma, Nutricia, Nestle and Bausch and Lomb outside the submitted work. L.A. Blum, E. Hamelmann and K. Nemat declare that they have no competing interests.